News
BPMC
103.36
+18.22%
15.93
Notable Monday Option Activity: SOFI, BPMC, TWLO
NASDAQ · 3h ago
Blueprint Medicines Shares Jump on View That Ayvakit Could Hit $2B in Revenue by 2030
Dow Jones · 4h ago
BPMC Makes Bullish Cross Above Critical Moving Average
NASDAQ · 5h ago
Blueprint Medicines Highlights 2024 Achievements and Future Growth
TipRanks · 6h ago
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Benzinga · 7h ago
Blueprint Medicines Price Target Cut to $124.00/Share From $135.00 by Wedbush
Dow Jones · 8h ago
Wedbush Reiterates Outperform on Blueprint Medicines, Lowers Price Target to $124
Benzinga · 9h ago
Blueprint Medicines (BPMC) Receives a Hold from Piper Sandler
TipRanks · 9h ago
Blueprint Medicines price target lowered to $124 from $135 at Wedbush
TipRanks · 9h ago
Blueprint Medicines: Promising Pipeline and Financial Strength Justify Buy Rating
TipRanks · 10h ago
Blueprint Medicines (BPMC) Gets a Buy from TD Cowen
TipRanks · 10h ago
BLUEPRINT MEDICINES CORP <BPMC.O>: WEDBUSH CUTS TARGET PRICE TO $124 FROM $135
Reuters · 11h ago
Blueprint Medicines Price Target Maintained With a $135.00/Share by Needham
Dow Jones · 12h ago
Positive Outlook for Blueprint Medicines: Promising Developments and Increased Sales Projections
TipRanks · 12h ago
Blueprint Medicines (BPMC) Receives a Hold from Barclays
TipRanks · 12h ago
Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target
Benzinga · 12h ago
Blueprint Medicines: Aggressive Growth Trajectory and Promising Future Drivers Justify Buy Rating
TipRanks · 12h ago
Blueprint Medicines: Balancing Promising Developments with Cautious Hold Rating Amid Competitive Landscape
TipRanks · 12h ago
Weekly Report: what happened at BPMC last week (0106-0110)?
Weekly Report · 14h ago
Reported Earlier, Blueprint Medicines Sees AYVAKIT 2024 Revenue At $475M–$480M (+130% YoY); Projects $4B SM Franchise Opportunity, Targets $2B AYVAKIT Revenue By 2030;
Benzinga · 15h ago
More
Webull provides a variety of real-time BPMC stock news. You can receive the latest news about Blueprint Medicines Corp through multiple platforms. This information may help you make smarter investment decisions.
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.